Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Multicenter, Double-blind, Placebo-controlled, Two-arm Parallel Group Trial of Rimonabant 20-mg od, for Inhibition of Atherosclerosis Progression Assessed by Carotid Artery Intima-media Thickness (CIMT), in Overweight Patients With Additional Risk Factors

NCT00228176 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00228176
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00228176 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Multicenter, Double-blind, Placebo-controlled, Two-arm Parallel Group Trial of Rimonabant 20-mg od, for Inhibition of Atherosclerosis Progression Assessed by Carotid Artery Intima-media Thickness (CIMT), in Overweight Patients With Additional Risk Factors
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Terminated
Start date
August 31, 2005
Completion date
April 30, 2009
Enrollment
661 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

arteriosclerosis, carotid artery plaque, metabolic syndrome x, obesity